Research ArticleArticle
Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire
Philip S. Helliwell, William Tillett, Robin Waxman, Laura C. Coates, Mel Brooke, Oliver FitzGerald, Jonathan C. Packham and Neil McHugh on behalf of the PROMPT Study Group
The Journal of Rheumatology February 2021, jrheum.201317; DOI: https://doi.org/10.3899/jrheum.201317
Philip S. Helliwell
This report is independent research funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P.S. Helliwell, Professor of Clinical Rheumatology, MA, DM, PhD, R. Waxman, Research Coordinator, MPH, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; W. Tillett, Consultant Rheumatologist, MBChB, PhD, Department of Pharmacy and Pharmacology, University of Bath, and Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; L.C. Coates, NIHR Clinician Scientist and Associate Professor, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; M. Brooke, Patient Partner; O. FitzGerald, Consultant Rheumatologist, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; J.C. Packham, Consultant Rheumatologist, BM, FRCP, DM, Division of Epidemiology and Public of Health, University of Nottingham, Nottingham, UK; N. McHugh, Professor of Rheumatology, MBChB, MD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. The authors declare no conflicts of interest relating to this manuscript. Address correspondence to Dr. P.S. Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk. Accepted for publication February 2, 2021.
William Tillett
This report is independent research funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P.S. Helliwell, Professor of Clinical Rheumatology, MA, DM, PhD, R. Waxman, Research Coordinator, MPH, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; W. Tillett, Consultant Rheumatologist, MBChB, PhD, Department of Pharmacy and Pharmacology, University of Bath, and Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; L.C. Coates, NIHR Clinician Scientist and Associate Professor, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; M. Brooke, Patient Partner; O. FitzGerald, Consultant Rheumatologist, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; J.C. Packham, Consultant Rheumatologist, BM, FRCP, DM, Division of Epidemiology and Public of Health, University of Nottingham, Nottingham, UK; N. McHugh, Professor of Rheumatology, MBChB, MD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. The authors declare no conflicts of interest relating to this manuscript. Address correspondence to Dr. P.S. Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk. Accepted for publication February 2, 2021.
Robin Waxman
This report is independent research funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P.S. Helliwell, Professor of Clinical Rheumatology, MA, DM, PhD, R. Waxman, Research Coordinator, MPH, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; W. Tillett, Consultant Rheumatologist, MBChB, PhD, Department of Pharmacy and Pharmacology, University of Bath, and Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; L.C. Coates, NIHR Clinician Scientist and Associate Professor, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; M. Brooke, Patient Partner; O. FitzGerald, Consultant Rheumatologist, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; J.C. Packham, Consultant Rheumatologist, BM, FRCP, DM, Division of Epidemiology and Public of Health, University of Nottingham, Nottingham, UK; N. McHugh, Professor of Rheumatology, MBChB, MD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. The authors declare no conflicts of interest relating to this manuscript. Address correspondence to Dr. P.S. Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk. Accepted for publication February 2, 2021.
Laura C. Coates
This report is independent research funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P.S. Helliwell, Professor of Clinical Rheumatology, MA, DM, PhD, R. Waxman, Research Coordinator, MPH, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; W. Tillett, Consultant Rheumatologist, MBChB, PhD, Department of Pharmacy and Pharmacology, University of Bath, and Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; L.C. Coates, NIHR Clinician Scientist and Associate Professor, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; M. Brooke, Patient Partner; O. FitzGerald, Consultant Rheumatologist, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; J.C. Packham, Consultant Rheumatologist, BM, FRCP, DM, Division of Epidemiology and Public of Health, University of Nottingham, Nottingham, UK; N. McHugh, Professor of Rheumatology, MBChB, MD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. The authors declare no conflicts of interest relating to this manuscript. Address correspondence to Dr. P.S. Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk. Accepted for publication February 2, 2021.
Mel Brooke
This report is independent research funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P.S. Helliwell, Professor of Clinical Rheumatology, MA, DM, PhD, R. Waxman, Research Coordinator, MPH, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; W. Tillett, Consultant Rheumatologist, MBChB, PhD, Department of Pharmacy and Pharmacology, University of Bath, and Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; L.C. Coates, NIHR Clinician Scientist and Associate Professor, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; M. Brooke, Patient Partner; O. FitzGerald, Consultant Rheumatologist, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; J.C. Packham, Consultant Rheumatologist, BM, FRCP, DM, Division of Epidemiology and Public of Health, University of Nottingham, Nottingham, UK; N. McHugh, Professor of Rheumatology, MBChB, MD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. The authors declare no conflicts of interest relating to this manuscript. Address correspondence to Dr. P.S. Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk. Accepted for publication February 2, 2021.
Oliver FitzGerald
This report is independent research funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P.S. Helliwell, Professor of Clinical Rheumatology, MA, DM, PhD, R. Waxman, Research Coordinator, MPH, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; W. Tillett, Consultant Rheumatologist, MBChB, PhD, Department of Pharmacy and Pharmacology, University of Bath, and Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; L.C. Coates, NIHR Clinician Scientist and Associate Professor, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; M. Brooke, Patient Partner; O. FitzGerald, Consultant Rheumatologist, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; J.C. Packham, Consultant Rheumatologist, BM, FRCP, DM, Division of Epidemiology and Public of Health, University of Nottingham, Nottingham, UK; N. McHugh, Professor of Rheumatology, MBChB, MD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. The authors declare no conflicts of interest relating to this manuscript. Address correspondence to Dr. P.S. Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk. Accepted for publication February 2, 2021.
Jonathan C. Packham
This report is independent research funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P.S. Helliwell, Professor of Clinical Rheumatology, MA, DM, PhD, R. Waxman, Research Coordinator, MPH, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; W. Tillett, Consultant Rheumatologist, MBChB, PhD, Department of Pharmacy and Pharmacology, University of Bath, and Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; L.C. Coates, NIHR Clinician Scientist and Associate Professor, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; M. Brooke, Patient Partner; O. FitzGerald, Consultant Rheumatologist, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; J.C. Packham, Consultant Rheumatologist, BM, FRCP, DM, Division of Epidemiology and Public of Health, University of Nottingham, Nottingham, UK; N. McHugh, Professor of Rheumatology, MBChB, MD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. The authors declare no conflicts of interest relating to this manuscript. Address correspondence to Dr. P.S. Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk. Accepted for publication February 2, 2021.
Neil McHugh
This report is independent research funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P.S. Helliwell, Professor of Clinical Rheumatology, MA, DM, PhD, R. Waxman, Research Coordinator, MPH, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; W. Tillett, Consultant Rheumatologist, MBChB, PhD, Department of Pharmacy and Pharmacology, University of Bath, and Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; L.C. Coates, NIHR Clinician Scientist and Associate Professor, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; M. Brooke, Patient Partner; O. FitzGerald, Consultant Rheumatologist, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; J.C. Packham, Consultant Rheumatologist, BM, FRCP, DM, Division of Epidemiology and Public of Health, University of Nottingham, Nottingham, UK; N. McHugh, Professor of Rheumatology, MBChB, MD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. The authors declare no conflicts of interest relating to this manuscript. Address correspondence to Dr. P.S. Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk. Accepted for publication February 2, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire
Philip S. Helliwell, William Tillett, Robin Waxman, Laura C. Coates, Mel Brooke, Oliver FitzGerald, Jonathan C. Packham, Neil McHugh
The Journal of Rheumatology Feb 2021, jrheum.201317; DOI: 10.3899/jrheum.201317
Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire
Philip S. Helliwell, William Tillett, Robin Waxman, Laura C. Coates, Mel Brooke, Oliver FitzGerald, Jonathan C. Packham, Neil McHugh
The Journal of Rheumatology Feb 2021, jrheum.201317; DOI: 10.3899/jrheum.201317